TimesSquare Capital Management’s Stemline Therapeutics, Inc. STML Stock Holding History

TimesSquare Capital Management’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-950,005	Closed	-$6.43M	–	246
2016 Q2	$6.43M	Sell	950,005 -216,000	-19%	-$1.36M	0.04%	225
2016 Q1	$5.43M	Sell	1,166,005 -19,175	-2%	-$93.6K	0.04%	224
2015 Q4	$7.48M	Sell	1,185,180 -10,100	-0.8%	-$82K	0.05%	225
2015 Q3	$10.6M	Sell	1,195,280 -28,900	-2%	-$303K	0.07%	220
2015 Q2	$14.4M	Sell	1,224,180 -87,700	-7%	-$1.22M	0.08%	222
2015 Q1	$19M	Buy	1,311,880 +471,500	+56%	+$7.22M	0.1%	214
2014 Q4	$14.3M	Buy	840,380 +39,155	+5%	+$565K	0.08%	216
2014 Q3	$9.98M	Buy	801,225 +3,200	+0.4%	+$39.4K	0.06%	225
2014 Q2	$11.7M	Sell	798,025 -13,025	-2%	-$200K	0.06%	219
2014 Q1	$16.5M	Buy	+811,050	New	+$19.7M	0.09%	216

Other funds holding STML

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TimesSquare Capital Management's STML Position: Q3 2016 in Review

TimesSquare Capital Management sold out of Stemline Therapeutics, Inc. (STML) in Q3 2016, closing a stake of 950,005 shares — an estimated $6.43M sold.

TimesSquare Capital Management first reported a position in STML in Q1 2014 and held it in 10 quarters. The position peaked at $19M in Q1 2015. 69 funds tracked by Wall St. Rank hold STML as of Q3 2016.

TimesSquare Capital Management reported no remaining Stemline Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
TimesSquare Capital Management sold 950,005 Stemline Therapeutics, Inc. shares in Q3 2016, an estimated $6.43M.
TimesSquare Capital Management first reported a position in Stemline Therapeutics, Inc. in Q1 2014 and held it in 10 quarters.
TimesSquare Capital Management's Stemline Therapeutics, Inc. position peaked at $19M in Q1 2015.
69 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q3 2016.

Based on TimesSquare Capital Management's 13F filing for Q3 2016, filed 10 Nov 2016.